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The London Olympic Games have recently ended with a great Closing Ceremony, and while some of 
us might still be in denial, the Olympic idea lives on. The focus is now on Rio de Janeiro in 2016! 
The Olympic motto Citius, Altius, Fortius (faster, higher, stronger) remains relevant in a number of 
spheres. Pierre de Coubertin, the father of the modern Olympic Games, expressed his thoughts in 
the Olympic creed: "The most important thing in the Olympic Games is not to win but to take part, 
just as the most important thing in life is not the triumph but the struggle...." 
 
In the field of transplantation, the ongoing struggle is to balance the risks of allograft rejection and 
infection with the benefits of living a normal life following transplantation, a challenge transplant 
patients face nearly every day. In particular, infectious complications within the first year after 
lung transplantation account for significant morbidity and mortality.1,2 A recent pediatric study 
showed an incidence of respiratory viral infection of 14% in the first year after lung 
transplantation.3 The incidence of respiratory viral infections in symptomatic adult lung transplant 
recipients (LTRs) ranges from 35-66%.4 Thus, prevention of viral infections is paramount, and the 
basis for prevention is adequate vaccination if available. 
 
Following the global 2009 H1N1 influenza virus pandemic, recommendations regarding the 
diagnosis, prevention and therapy of influenza were issued by the American Society of 
Transplantation, in view of the risk of severe influenza infection and influenza-related 
complications in solid organ transplant recipients (SOTRs).5 A specific concern in LTRs is the 
potential association between respiratory viral infections and acute allograft rejection and the 
subsequent development of bronchiolitis obliterans syndrome (BOS). A recent literature review by 
Vu et al investigating the relationship between viral respiratory infection and graft complications in 
adult LTRs did not conclusively support an association between respiratory viral infection and 
acute lung rejection and the subsequent development of BOS, mainly due to the heterogeneity and 
the retrospective design of published studies to date.6 In the pediatric lung transplant population, 
respiratory viral infection has been associated with a 2.5-fold decrease in 1-year survival but it was 
not linked with the development of BOS in retrospective studies.3,7 Failure to demonstrate a 
relationship however should not be misconstrued as evidence of the lack of a causal link. Hence, a 
National Institutes of Health study in pediatric lung transplantation is currently underway to 
investigate the potential interaction between respiratory viral infections and BOS utilizing improved 
molecular diagnostics for respiratory viruses and increased patient surveillance 
(https://www.ctotc.org/). 
 
Usually, transplant centers recommend LTRs receive vaccination with the annual influenza vaccine 
from as early as 3-6 months post-transplant; however, there is a lack of data regarding the most 
suitable time point for vaccine administration and concerns exist about an impaired vaccine 
response.8 Vaccine antibody response is usually used as a surrogate marker of vaccine efficacy; 
however, this is not equal with protection. Factors that lead to non-response in LTRs after 
influenza vaccination have yet to be established. A systemic review and meta-analysis assessing 
influenza vaccination for immunocompromised patients showed a significant effect in the 
prevention of an influenza-like illness and no consistent evidence of safety concerns or serious 
adverse events (AEs) after influenza vaccination.9 A recent observational study from Zurich showed 
that nearly 50% of LTRs reported no AEs after H1N1 vaccination, with the remaining LTRs mostly 
having minor/moderate AEs, such as local reactions at the injection site.10 Serious and reportable 
AEs occurred in 6% of LTRs. The effectiveness of H1N1 vaccination was reported as >90% in the 
study; however, the effectiveness was only assessed based on protection from subsequent H1N1 
infection and not on vaccine antibody response. 
 
Even though the benefits of immunization have been shown, there is evidence that exposure to 
influenza antigens after vaccination might directly activate alloreactive T and B cells, an effect 
labelled "heterologous immunity".11 Danziger-Isakov et al investigated effects of influenza 
immunization on humoral and cellular alloreactivity in healthy controls (N=30) and SOTRs (N=17), 
demonstrating that influenza vaccination induced virus-specific reactive humoral and cellular 
responses in both groups.11 In a recent Swiss study in kidney transplant recipients de novo anti-
HLA antibodies were detected using single antigen beads technology following one dose of seasonal 
influenza and two doses of adjuvanted influenza/H1N1 vaccines.12 Antibodies were both donor-
specific and non-donor-specific and mainly low level. However, in an accompanying editorial in the 
same edition of the American Journal of Transplantation, Kumar and Danziger-Isakov rightly point 
out that increased HLA alloantibody titers could potentially be due to sub-clinical or undiagnosed 
influenza infection during the H1N1 pandemic, and clinical rejection in two study patients could be 
explained by other factors.13 Further, Kumar and Danziger-Isakov recommend that the study 
results of Katerinis should be interpreted with caution so as to balance any potential vaccination-
associated risks with the well described benefits in disease prevention. 
 
In conclusion, the benefits of influenza vaccination and its effectiveness in preventing viral disease 
seem to clearly outweigh the risks of vaccine-related AEs that are predominantly minor and self-
limiting in nature. In view of the emerging evidence of the potential impact of influenza vaccination 
on recipients' alloresponse, further research is required to investigate its impact on long-term 
allograft function and the potential association with the development of BOS. As Pierre de 
Coubertin said, the essential thing is not to have conquered but to have fought well.... 
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